Frontier Wealth Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Frontier Wealth Management’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18	Closed	-$192K	–	333
2019 Q4	$192K	Hold	18	–	–	0.03%	286
2019 Q3	$119K	Hold	18	–	–	0.02%	294
2019 Q2	$126K	Hold	18	–	–	0.02%	292
2019 Q1	$95K	Hold	18	–	–	0.01%	352
2018 Q4	$108K	Hold	18	–	–	0.02%	344
2018 Q3	$56K	Hold	18	–	–	0.01%	385
2018 Q2	$72K	Hold	18	–	–	0.01%	374
2018 Q1	$90K	Buy	+18	New	+$89.2K	0.01%	376

Other funds holding ATXI

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Frontier Wealth Management's ATXI Position: Q1 2020 in Review

Frontier Wealth Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2020, closing a stake of 18 shares — an estimated $192K sold.

Frontier Wealth Management first reported a position in ATXI in Q1 2018 and held it in 8 quarters. The position peaked at $192K in Q4 2019. 19 funds tracked by Wall St. Rank hold ATXI as of Q1 2020.

Frontier Wealth Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Frontier Wealth Management sold 18 Avenue Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $192K.
Frontier Wealth Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2018 and held it in 8 quarters.
Frontier Wealth Management's Avenue Therapeutics, Inc. Common Stock position peaked at $192K in Q4 2019.
19 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Frontier Wealth Management's 13F filing for Q1 2020, filed 8 May 2020.